Muscle Wasting News and Research

RSS

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.

17 Dec 2013

Chronic bronchitis could indicate COPD subtype

Chronic bronchitis is common among patients with chronic obstructive disease and may represent a subtype of the disease that places patients at risk for increased severity and exacerbations, say researchers.

22 Nov 2013

Young adults who had childhood cancer more likely to be frail than their peers

Young adults who survived childhood cancer are more likely than their peers to be frail, according to a St. Jude Children's Research Hospital study, which reported the condition is more common among female survivors than women decades older. The research appears in the November 18 online edition of the Journal of Clinical Oncology.

18 Nov 2013

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

A new study reveals that tumors release factors into the bloodstream that inhibit the repair of damaged muscle fibers, and that this contributes to muscle loss during cancer wasting.

24 Oct 2013

Research Institute receives Fast Track status for its gene therapy product for treatment of SMA

AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children's Hospital received Fast Track designation from the U.S. Food and Drug Administration for its scAAV9.CB.SMN gene therapy product for the treatment of spinal muscular atrophy (SMA).

19 Oct 2013

Survivors of critical illness experience significant skeletal muscle weakness

Zudin A. Puthucheary, M.R.C.P., of University College London, England, and colleagues conducted a study to characterize and evaluate the time course and pathophysiology of acute muscle loss in critical illness.

10 Oct 2013

Researchers say type 2 diabetes status should be taken into account in future BMI-mortality studies

The relationship between body mass index (BMI) appears to be stronger in adults without diabetes than those with existing diabetes. These findings- are published in the Journal of General Internal Medicine- in a study by Chandra Jackson of the Harvard School of Public Health and colleagues.

13 Aug 2013

Weight and mortality relationship appears to be stronger in adults without diabetes

Researchers ask diabetes status be taken into account in population studies that link weight and mortality. The relationship between body mass index (BMI) appears to be stronger in adults without diabetes than those with existing diabetes. These findings¹ are published in the Journal of General Internal Medicine² in a study by Chandra Jackson of the Harvard School of Public Health and colleagues.

12 Aug 2013

Gene combination therapy repairs and prevents future damage of muscles caused by DMD

New research on two promising gene therapies suggests that combining them into one treatment not only repairs muscle damage caused by Duchenne muscular dystrophy, but also prevents future injury from the muscle-wasting disease.

12 Aug 2013

Trace substance in sugar improves muscle regeneration in mouse model with muscular dystrophy

A trace substance in caramelized sugar, when purified and given in appropriate doses, improves muscle regeneration in a mouse model of Duchenne muscular dystrophy. The findings are published today, Aug. 1, in the journal Skeletal Muscle.

2 Aug 2013

Study provides more reliable estimate of the likely risk of disability associated with diabetes

Older adults with diabetes are at least 50% more likely to have a physical disability than those without diabetes, according to the results of a new systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology.

25 Jul 2013

TSRI scientists identify small molecules to control genetic defect responsible for muscular dystrophy

For the first time, scientists from the Florida campus of The Scripps Research Institute have identified small molecules that allow for complete control over a genetic defect responsible for the most common adult onset form of muscular dystrophy.

28 Jun 2013

Available drugs may have a dramatic impact on children stricken with Tay-Sachs disease

A team of researchers has made a significant discovery which may have a dramatic impact on children stricken with Tay-Sachs disease, a degenerative and fatal neurological condition that often strikes in the early months of life.

7 Jun 2013

Cedars-Sinai team awarded grant to study cardiac stem cell treatment for Duchenne muscular dystrophy

Newport Beach-based nonprofit Coalition Duchenne has awarded a $150,000 grant to a Cedars-Sinai Heart Institute team investigating whether an experimental cardiac stem cell treatment could be used to treat Duchenne muscular dystrophy patients who have developed heart disease.

30 May 2013

Researchers identify how proteasome takes care of unwanted, potentially toxic proteins

Proteins, unlike diamonds, aren't forever. And when they wear out, they need to be degraded in the cell back into amino acids, where they will be recycled into new proteins.

29 Apr 2013

GTx to continue two pivotal Phase III clinical trials of enobosarm

GTx, Inc. today announced that a per protocol safety review of unblinded safety data on Friday April 12, 2013, by an independent Data Safety Monitoring Board, resulted in a determination that GTx continue as planned its two pivotal Phase III clinical trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer.

16 Apr 2013

Johns Hopkins scientist awarded Ho-Am prize for discovery of myostatin

South Korea's Ho-Am Foundation announced that Johns Hopkins researcher Se-Jin Lee, M.D., Ph.D., has won this year's Ho-Am Prize in Medicine.

5 Apr 2013

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy, announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV.

21 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Drugs that combat ageing may be available within five years

Drugs that combat ageing may be available within five years, following landmark work led by an Australian researcher.

11 Mar 2013